Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Padiatrie Und Grenzgebiete|January 1, 1991
[Bacterial bone and joint infections in childhood--a review. 2. Septic bursitis]W Handrick, W Tischer, D Brock, et al.Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II clinical trial of high-dose recombinant human tumor necrosis factorH Lenk, S Tanneberger, U Müller, et al.European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [Et Al] = Zeitschrift Fur Kinderchirurgie|October 29, 2005
Acute portal vein thrombosis after splenic embolization and splenectomy for autoimmune pancytopeniaJ Nounla, I Sorge, F Deckert, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|August 12, 1999
German recommendations for immune tolerance therapy in type A haemophiliacs with antibodiesH H Brackmann, H Lenk, I Scharrer, et al.The Journal of Clinical Investigation|March 15, 1996
Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia AJ G Gilles, B Desqueper, H Lenk, et al.Hamostaseologie|September 11, 2012
[Haemophilia treatment centres in Germany]R Zimmermann, B Eifrig, H Lenk, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|September 27, 2003
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitroJ Astermark, J Voorberg, H Lenk, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|January 3, 2001
Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assayJ Klinge, G Auerswald, U Budde, et al.Oncology|January 1, 1990
Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patientsH Lenk, S Tanneberger, N Wiener, et al.Klinische Padiatrie|September 23, 1998
[Clinical aspects and epidemiology of hepatitis C in immunosuppressed children with mostly oncologic diseases]K Rieske, M Domula, U G Liebert, et al.Pageof 5